News & Updates

Treatment with metformin, along with lifestyle changes, initiated for the prevention of diabetes does not appear to reduce the risk of age-related macular degeneration, a study has found.

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Adding a once-weekly dose of semaglutide to lifestyle intervention successfully reduced body mass index (BMI) in adolescents with obesity, according to results of the phase IIIa STEP TEENS trial.

Neutrophil-to-lymphocyte ratio (NLR) is a significant predictor of new-onset ischaemic stroke in Chinese patients with type 2 diabetes mellitus (T2DM), the population-based Hong Kong Diabetes Study has shown.

Despite reducing triglyceride levels, pemafibrate does not reduce the risk of cardiovascular (CV) events among patients with type 2 diabetes (T2D) and hypertriglyceridemia, according to results of the PROMINENT trial presented at AHA 2022.

For individuals with obesity who are scheduled to undergo bariatric surgery, faecal microbiota transplantation (FMT) from a lean donor does not appear to help reduce weight before or after the procedure, according to a study.

Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).

In a study presented at ASH 2022, obesity was found to be associated with adverse outcomes in individuals with primary immune thrombocytopenia (ITP; formerly known as thrombocytopenia purpura).